헤더 로고

• All
• Day 1: March 26 (Thu)
• Day 2: March 27 (Fri)
• Day 3: March 28 (Sat)

Day 2: March 27 (Fri)

• Microbial Molecules as Emerging Biomarkers in Hematologic Diseases Christoph K. Stein-Thoeringer
  University Clinic Tübingen, Germany CV
• Gut Microbiome as a Predictive Biomarker and Emerging Intervention Target in DLBCL Woorim Kang
  Kangwon National University, Korea CV
• Microbiome in Allogeneic Hematopoietic Cell Transplantation & Immunotherapy Jonathan U. Peled
  Memorial Sloan Kettering Cancer Center, USA CV

Day 2: March 27 (Fri)

• A Personalized Approach to Immune Therapies for Cancer: One Drug, One Patient Larry W. Kwak
  City of Hope, USA CV
• Paradigm Shift of DLBCL Treatment Based on Bispecific Abs Won Seog Kim
  Sungkyunkwan University School of Medicine, Korea
• Paradigm shift of DLBCL Treatment Based on MRD-Driven Approach Ash A. Alizadeh
  Stanford University, USA CV

Day 2: March 27 (Fri)

• Iron Deficiency & Iron Metabolism Jeong-Ok Lee
  Seoul National University College of Medicine, Korea
• Hereditary Hemolytic Anemia Heewon Chueh
  Inje University Haeundae Paik Hospital, Korea CV
• Cold Agglutinin Disease Dae-Ho Choi
  Sungkyunkwan University School of Medicine, Korea CV

Day 2: March 27 (Fri)

• The Present and Future of Hematopoietic Stem Cell Gene Therapies Cynthia E. Dunbar
  National Institutes of Health, USA CV

Day 2: March 27 (Fri)

• Menin Inhibitors and Epigenetic Therapy in KMT2A-rearranged ALL Elisabeth Salzer
  St. Anna Children's Hospital, Austria
• Virus-specific and Next-generation T-cell Therapy in Pediatric Hematologic Malignancy Catherine Bollard
  Children’s National Hospital, USA
• Pediatric Cancer Survivorship and Long-Term Toxicities Sharon M. Castellino
  Emory University School of Medicine, USA CV

Day 2: March 27 (Fri)

• Leukemia Stem Cells, Clonal Evolution, and Immune Evasion in AML: Translational Insights and Therapeutic Opportunities Ravindra Majeti
  Stanford University, USA CV
• Menin Inhibition in AML: Evolving Frontiers in Targeted Therapy Eytan M. Stein
  Memorial Sloan Kettering Cancer Center, USA CV
• HMA + Venetoclax + Targeted Agents: Clinical Evidence and Future of Triplet Therapy in AML Tapan Kadia
  The University of Texas MD Anderson Cancer Center, USA CV

Day 2: March 27 (Fri)

• Real-World Effectiveness of Immunotherapy in Hematologic Malignancies: Evidence from Big Data Sung-Soo Park
  College of Medicine, The Catholic University of Korea, Korea CV
• Digital Healthcare Innovation: Real-World Applications of Big Data and AI Yoon Sup Choi
  Digital Healthcare Partners, Korea CV
• Wise Hematology Life: Use of AI Ki-Hyun Jeon
  Seoul National University College of Medicine, Korea CV

Day 2: March 27 (Fri)

• Real World Long Term TPO-RA: Sustaining Remission or Time to Stop? Nichola Cooper
  Imperial College Healthcare NHS Trust, UK
• A New Chapter in ITP management - Updated trials Jun Ho Jang
  Sungkyunkwan University School of Medicine, Korea
• Caplacizumab and the Changing Landscape of TTP Management Shruti Chaturvedi
  Johns Hopkins University School of Medicine, USA CV

Day 2: March 27 (Fri)

• AL Amyloidosis: A Comprehensive Update from Fundamentals to Emerging Therapies Efstathios Kastritis
  National and Kapodistrian University of Athens, Greece CV
• Monoclonal Gammopathy and the Kidney: A Comprehensive Approach to MGRS Nelson Leung
  Mayo Clinic, USA CV
• POEMS Syndrome: From Longitudinal Clinical Experience to Translational Insights Emiko Sakaida
  Chiba University Hospital, Japan CV

Day 2: March 27 (Fri)

• CRS and ICANS: Early Detection and Personalized Management Jinchul Kim
  Inha University College of Medicine, Korea CV
• Prolonged Cytopenia after TCEs: Mechanisms, Biomarkers, and Risk Stratification Sang Eun Yoon
  Sungkyunkwan University School of Medicine, Korea CV
• Preventing Infections in TCEs: Risk Stratification and Prophylaxis Ja Min Byun
  Seoul National University College of Medicine, Korea CV